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ABSTRACT
Objective: Drug interaction is one factor that contributes to drug-related problems. The hospitalized patients in intensive care units (ICU) have a 
higher risk for developing drug interactions. The purpose of this study was to evaluate the potency of significant drug interactions in ICU patients.
Methods: Drug-drug interactions from patient’s medical records from ICU of Arifin Achmad General Hospital in Pekanbaru, Province of Riau, Indonesia 
at period of July to December 2015 were assessed. Drug Interaction Checker (Medscape) software was used to identify potential drug interactions.
Results: This study included 28 ICU patients (mean age, 48 years) who had the potency to drug interactions based on the software. Of these, 29% were 
male and 71% were female patients. The number of drugs that were given to patients was 3-13 drugs (average 7 drugs per patient). There were 
122 potential drug-drug interactions found in this study, including 43% potency of minor or non-significant, 52% potency of significant, 3% potency of 
serious, and 2% potency of contraindicated drug interactions. A total of 67% were pharmacodynamics and 33% were pharmacokinetics interactions. 
Dexamethasone, ketoprofen, ketorolac, furosemide, nifedipine, and enoxaparin were among drugs with the highest frequency of potential drug 
interactions.
Conclusion: Significant drug-drug interactions were prevalent in the ICU patients. This may be due to the complexity of the pharmacotherapies 
administered. The health professionals who provide care to these patients should be aware to identify and prevent possible drug events.
Keywords: Significant drug interactions, Intensive care unit, Potency, Drug-related problems.
INTRODUCTION
Concurrent administration of drugs is one factor that can alter the 
response to drugs. The drug interactions may be beneficial or harmful, 
depending on various factors related to the medication, the patient 
or the conditions under which the medication is used [1]. Beneficial 
interactions can increase efficiency or allow the reduction of the 
dose. The harmful interactions can increase the incidence of adverse 
reactions and cause a reduction of the effects or results contrary to 
those expected [2]. Studies have shown a positive correlation between 
many different drugs and drug interactions. The prevalence of potential 
drug interactions is 3-5% in patients who receive 3-10 drugs and will 
increase to 20% when they are given 10-20 drugs [3].
There are several mechanisms by which drugs may interact, but most 
can be categorized as pharmacokinetic interactions, pharmacodynamics 
interactions, or combined interactions. Knowledge of the mechanism 
by which a given drug interaction occurs is clinically useful, since the 
mechanism may influence both the time course and the methods of 
preventing the interaction [4].
The hospitalized patients in intensive care unit (ICU) have a higher risk 
for developing drug interactions than patients from other care units. 
In addition to multiple drugs therapy, patients in the ICU presented a 
risk due to the severity of disease and organ failure. Drug interactions 
contribute to the incidence of adverse reactions in ICU and often constitute 
an unrecognized complication in pharmacotherapy. The prevalence of 
potential drug interactions in the ICU ranged from 44.3% to 86% [5,6].
The purpose of this study was to evaluate the potency of significant 
drug interactions in hospitalized patients at the ICU of Arifin Achmad 
General Hospital in Pekanbaru, Province of Riau, Indonesia. This study 
is useful to circumvent adverse drug reaction and to increase drug 
efficacy.
METHODS
This was a prospective study conducted in the ICU of Arifin Achmad 
General Hospital in Pekanbaru, Province of Riau, Indonesia. The 
medical records of patients, hospitalized in the ICU from July to 
December 2015, were included in the research. The characteristic 
information and main diagnosis were extracted from the patients’ 
medical records. Information regarding medications administered was 
collected from the medical prescription documentation. Only patients 
aged over 18 years old were included in this study. We constructed a 
specific instrument to assist in data collection. Using this data collection 
instrument, information was collected from patients, including age, 
gender, primary diagnoses (according to the International Statistical 
Classification of Diseases and Related Health Problems [ICD 10]), and 
information about administered drugs.
Potential drug interactions are interactions that could theoretically 
occur during patient’s pharmacotherapy treatment, and which may 
or may not be clinically manifested. In the present investigation, the 
terminology “drug interaction” will be used to refer to the area that 
includes drug-drug interaction.
For the identification of potential drug-drug interactions, Drug Interaction 
Checker (Medscape) software was used. This software has the adequate 
sensitivity to detect drug interactions in the hospital. The Drug Interaction 
Checker software provides information on clinical outcomes or adverse 
drug reactions resulting from the interaction, and characterizes the 
mechanism of action. It classifies the interactions in relation to severity 
in four categories (minor or non-significant, significant, serious, and 
contraindicated). The mechanisms underlying the interaction were 
classified into pharmacokinetic and pharmacodynamic.
The data were stored in Microsoft® Excel 2010. Descriptive analysis was 
performed using frequency distribution for the categorical variables. 
The study was approved by the Ethics Committee of Faculty of Medicine 
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University of Riau (No: 62/UN.19.5.1.1.8/UEPKK/2015) and consistent 
with the standards of ethics in research involving humans.
RESULTS
This study included 39 medical records from patients who hospitalized 
in the ICU, and of these, 28 ICU’s patients had the potency to drug 
interactions based on the software, 20 (71%) of which were from 
female patients. The mean age was 48 years (±19.0), with a minimum 
age of 21 and a maximum of 85 years. The number of drugs that were 
given to patients was 3-13 drugs (7 drugs per patient in average). 
The most common drugs that were administered to the patients were 
antimicrobial, gastrointestinal, and analgesic, or antipyretics drugs. The 
most common diagnoses were obstetric and gynecologic, surgical, and 
neurological disorders.
The total number of potential drug interactions was 122. The average 
number of drug interactions per patient was 4, with a minimum 1 and a 
maximum of 18 drug interactions.
Table 1 presents the classification of potential drug interactions with 
respect to severity. The severe and moderate potential interactions 
(significant, serious, and contraindicated), together, accounted for 57% 
of the interactions.
There was a predominance of potential drug interactions with 
a pharmacodynamic mechanism of action, with a frequency of 
82 (67%). The potential drug interactions of pharmacokinetic 
mechanism totaled 40 (33%). According to analyses of the case 
distribution of potential pharmacokinetic drug interactions, the 
metabolism process was responsible for most of the potential 
interactions. A pharmacokinetic interaction can be determined by 
more than one process.
The most frequent significant drug interactions are listed in Table 2. 
Dexamethasone, ketoprofen, ketorolac, furosemide, nifedipine, and 
enoxaparin were identified as the drugs with the highest frequency of 
potential drug interactions.
DISCUSSION
This study showed that 72% of cases had the potency of drug 
interactions. Similarly, Reis and Cassiani and Carvalho et al. 
reported a 70% prevalence of potential drug interactions in the ICU 
patients [7,8]. However, a much lower frequency of drug interactions 
(39.22%) was reported by Annisa and Abdullah in geriatric 
patients [9]. A literature review by Espinosa-Bosch et al. found that 
the prevalence of drug interactions in hospitalized patients in Spain 
and England was 15-45% [10]. Differences in the level of sensitivity 
and specificity of the methodologies used in identifying the potential 
drug interactions may explain the discrepancy between these 
studies.
Although the identification of drug interactions using a software 
approach detects potential interactions, this does not mean that 
possible adverse events will manifest clinically in all patients with 
those potential drug interactions [8]. The software is an important tool 
to verify potential drug interactions, but it generally produces a high 
signal level that may indicate a higher prevalence of potential drug 
interactions [11].
The average age of subjects in this study was 48 years. This finding was 
similar to a study reported previously [8]. Age is an important factor 
in drug interactions as described by Becker et al. who found that the 
prevalence of drug interactions was increased from 10.5% to 19.2% in 
patients over 55 years. Patients over 55 years are susceptible for drug-
related problems [12].
Based on the common diagnoses, most of the patients suffer from 
obstetric and gynecological diseases. This condition corresponds to 
the characteristic of the subject (71% were female). In contrast, Reis 
and Cassiani and Carvalho et al. and Bregnhøj et al. revealed that 
potential drug interactions occurred in patients with cardiovascular 
diseases [7,8,13]. Patients with the pathological condition have 
an increased risk for drug interactions through pharmacokinetic 
mechanism [2].
The number of drugs prescribed is one of the determinants of drug 
interactions. The average number of drugs that were given to patients 
in this study was 7 drugs. A similar result was found in a study by 
Bregnhøj et al. [13]. On the other hand, a Brazilian study found 
that the average number of drugs administered to patients was 12 
drugs [7]. Polypharmacy treatment can increase the potency of drug 
interactions [2,14]. We found 122 potential drug interactions (the 
average number of drug interactions per patient was 4) in this study. 
The combined use of two or more drugs, each of which has toxic 
effects on the same organ, can greatly increase the likelihood of organ 
damage. For example, concurrent administration of two nephrotoxic 
drugs can produce kidney damage; even though, the dose of either 
drug alone may be insufficient to produce toxicity. Furthermore, some 
drugs can synergistically enhance the organ toxicity of other drugs 
even though the enhancing drug has no intrinsic toxic effect on that 
organ [4].
Most of the potential drug interactions were severe and moderate 
interactions (57%). This finding was consistent with a study by 
Carvalho et al. [8]. The severity of drug interaction in the samples 
studied was better than in other national study, where the prevalence of 
moderate interaction was 89.05% [9]. Based on possible mechanisms, 
pharmacodynamic was more often than pharmacokinetic interactions 
as the underlying mechanism in this study. Potential pharmacodynamic 
interactions showed a significant prevalence in the present study. When 
drugs with similar pharmacologic effects are administered concurrently, 
an additive or synergistic response is usually occurred. These drugs may 
or may not act on the same receptor to produce such effects. Conversely, 
drugs with opposing pharmacologic effects may reduce the response to 
one or both drugs. Pharmacodynamic drug interactions are relatively 
common in clinical practice, but adverse effects can be minimized if 
clinicians understand the pharmacology of the drugs involved. In this 
way, the drug interactions can be prevented [4]. Changes in the volume 
of drug distribution and other pharmacokinetic factors can also pose 
a safety risk for of in these patients. The activity of cytochrome P450 
and the effect of P-glycoprotein are important determinants of the 
pharmacokinetic processes in a significant number of drugs. They 
Table 1: Classification of potential drug interactions identified 





Contra indicated 2 (2)
Table 2: The most frequent significant drug interactions in 








Others (26 kind of drugs) 52 (43)
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are also involved in the mechanisms of clinically important drug 
interactions in ICU [2].
A strategy to anticipate potential drug interactions is by planning the 
schedule of drug administration. This aspect is more easily handled 
when the drugs are administered in a single dose. Complexity arises 
with multiple schemes of drug administration [15]. However, planning 
the schedule has little implication in the prevention of potential 
pharmacokinetic interactions that involve either the metabolism 
process or pharmacodynamics. For these categories, the main 
preventive measures may include strategies, such as avoiding drug 
combination, adjusting the dose, or monitoring for early detection of 
adverse effects [8].
The most frequent drug involved in drug interactions in this study 
was dexamethasone. Dexamethasone is induced and metabolized 
by CYP3A4. Inhibitors of CYP3A4 increases plasma dexamethasone 
concentrations, whereas the inducers of CYP3A4 decreases plasma 
dexamethasone concentrations [16]. Ketoprofen was also another 
agent frequently identified in drug interactions in this study. The 
possibility of increased interaction is increased when ketoprofen 
is given concomitantly with highly bound drugs [17]. Another non-
steroidal anti-inflammation drug that we found in the present study 
was ketorolac. Ketorolac is highly bound to human plasma protein 
(mean 99.2%). There is no evidence in animal or human studies that 
ketorolac tromethamine induces or inhibits hepatic enzymes capable of 
metabolizing itself or other drugs [18].
Furosemide, nifedipine, and enoxaparin also exhibited significant 
drug interactions. Furosemide may increase the ototoxic potential of 
aminoglycoside antibiotics, especially in the presence of impaired renal 
function. Furosemide should not be used concomitantly with ethacrynic 
acid due to the possibility of ototoxicity. Patients receiving high doses 
of salicylates concomitantly with furosemide may experience salicylate 
toxicity at lower doses due to competitive renal excretory sites. In 
addition, nephrotoxicity of nephrotoxic drugs, such as cisplatin, can be 
enhanced by furosemide. This usually occurs when furosemide is given 
in a high dose or in the presence of positive fluid balance as a result of 
forced diuresis during cisplatin treatment [19].
Furthermore, nifedipine is metabolized by CYP3A4. Co-
administration of nifedipine with phenytoin, an inducer of CYP3A4, 
lowers the systemic exposure to nifedipine by approximately 70%. 
CYP3A inhibitors, such as fluconazole, itraconazole, clarithromycin, 
erythromycin, nefazodone, fluoxetine, saquinavir, indinavir, and 
nelfinavir, can increase the exposure to nifedipine when co-
administered [20]. Agents that can enhance the risk of hemorrhage 
should be discontinued before the initiation of enoxaparin. If co-
administration is essential, it is recommended to perform close 
clinical and laboratory monitoring [21].
The number of samples that included in this study represents the 
number of patients hospitalized in the ICU of Arifin Achmad General 
Hospital for the period of study. The sample number is also associated 
with the inclusion criteria and the capacity of beds in ICU.
This study contributes significantly to the practice of critical care 
nursing by presenting the profile of drug interactions in the ICU’s 
patients, building an important tool for planning and interventions for 
improving patient safety in ICU. It is essential to implement strategies 
that help the health-care team to identify potential interactions. These, 
in turn, would be useful to the prevention and monitoring of patients at 
risk of developing drug interactions.
CONCLUSION
This study showed that potency of significant drug interactions is 
prevalent in the ICU due to the complexity of the pharmacotherapies 
administered. The health professionals who provide care to these 
patients should be aware to identify and prevent possible drug 
events.
Health professionals’ knowledge about drug interactions and their 
clinical significance could help to predict drug interactions and 
minimize the negative impacts through adequate monitoring, when 
the combination is unavoidable. This kind of attitude of the health-care 
team contributes to the optimization and safety of pharmacotherapy in 
critically ill patients.
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